Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population
• The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HI...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Fordan, Sally [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management - Scheen, Marc ELSEVIER, 2022, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:91 ; year:2017 ; pages:79-83 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jcv.2017.04.005 |
|---|
| Katalog-ID: |
ELV030212227 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV030212227 | ||
| 003 | DE-627 | ||
| 005 | 20230623204105.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2017.04.005 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017002000003.pica |
| 035 | |a (DE-627)ELV030212227 | ||
| 035 | |a (ELSEVIER)S1386-6532(17)30115-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 616.019405 |q OCLC |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Fordan, Sally |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population |
| 264 | 1 | |c 2017 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. | ||
| 650 | 7 | |a Supplemental |2 Elsevier | |
| 650 | 7 | |a HIV |2 Elsevier | |
| 650 | 7 | |a Geenius |2 Elsevier | |
| 650 | 7 | |a Performance |2 Elsevier | |
| 650 | 7 | |a Algorithm |2 Elsevier | |
| 700 | 1 | |a Bennett, Berry |4 oth | |
| 700 | 1 | |a Lee, Meghan |4 oth | |
| 700 | 1 | |a Crowe, Susanne |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Scheen, Marc ELSEVIER |t Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |d 2022 |g Amsterdam [u.a.] |w (DE-627)ELV007727844 |
| 773 | 1 | 8 | |g volume:91 |g year:2017 |g pages:79-83 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jcv.2017.04.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |j Immunologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 91 |j 2017 |h 79-83 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s f sf |
|---|---|
| matchkey_str |
fordansallybennettberryleemeghancrowesus:2017----:oprtvpromnefhgeisi1i2upeetletnlrdsul |
| hierarchy_sort_str |
2017 |
| bklnumber |
44.45 |
| publishDate |
2017 |
| allfields |
10.1016/j.jcv.2017.04.005 doi GBVA2017002000003.pica (DE-627)ELV030212227 (ELSEVIER)S1386-6532(17)30115-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 616.019405 OCLC 610 VZ 44.45 bkl Fordan, Sally verfasserin aut Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population 2017 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm Elsevier Bennett, Berry oth Lee, Meghan oth Crowe, Susanne oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:91 year:2017 pages:79-83 extent:5 https://doi.org/10.1016/j.jcv.2017.04.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 91 2017 79-83 5 045F 610 |
| spelling |
10.1016/j.jcv.2017.04.005 doi GBVA2017002000003.pica (DE-627)ELV030212227 (ELSEVIER)S1386-6532(17)30115-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 616.019405 OCLC 610 VZ 44.45 bkl Fordan, Sally verfasserin aut Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population 2017 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm Elsevier Bennett, Berry oth Lee, Meghan oth Crowe, Susanne oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:91 year:2017 pages:79-83 extent:5 https://doi.org/10.1016/j.jcv.2017.04.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 91 2017 79-83 5 045F 610 |
| allfields_unstemmed |
10.1016/j.jcv.2017.04.005 doi GBVA2017002000003.pica (DE-627)ELV030212227 (ELSEVIER)S1386-6532(17)30115-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 616.019405 OCLC 610 VZ 44.45 bkl Fordan, Sally verfasserin aut Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population 2017 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm Elsevier Bennett, Berry oth Lee, Meghan oth Crowe, Susanne oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:91 year:2017 pages:79-83 extent:5 https://doi.org/10.1016/j.jcv.2017.04.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 91 2017 79-83 5 045F 610 |
| allfieldsGer |
10.1016/j.jcv.2017.04.005 doi GBVA2017002000003.pica (DE-627)ELV030212227 (ELSEVIER)S1386-6532(17)30115-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 616.019405 OCLC 610 VZ 44.45 bkl Fordan, Sally verfasserin aut Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population 2017 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm Elsevier Bennett, Berry oth Lee, Meghan oth Crowe, Susanne oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:91 year:2017 pages:79-83 extent:5 https://doi.org/10.1016/j.jcv.2017.04.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 91 2017 79-83 5 045F 610 |
| allfieldsSound |
10.1016/j.jcv.2017.04.005 doi GBVA2017002000003.pica (DE-627)ELV030212227 (ELSEVIER)S1386-6532(17)30115-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 616.019405 OCLC 610 VZ 44.45 bkl Fordan, Sally verfasserin aut Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population 2017 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm Elsevier Bennett, Berry oth Lee, Meghan oth Crowe, Susanne oth Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:91 year:2017 pages:79-83 extent:5 https://doi.org/10.1016/j.jcv.2017.04.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 91 2017 79-83 5 045F 610 |
| language |
English |
| source |
Enthalten in Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management Amsterdam [u.a.] volume:91 year:2017 pages:79-83 extent:5 |
| sourceStr |
Enthalten in Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management Amsterdam [u.a.] volume:91 year:2017 pages:79-83 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Immunologie |
| institution |
findex.gbv.de |
| topic_facet |
Supplemental HIV Geenius Performance Algorithm |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| authorswithroles_txt_mv |
Fordan, Sally @@aut@@ Bennett, Berry @@oth@@ Lee, Meghan @@oth@@ Crowe, Susanne @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV007727844 |
| dewey-sort |
3610 |
| id |
ELV030212227 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030212227</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623204105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2017.04.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017002000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030212227</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(17)30115-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.019405</subfield><subfield code="q">OCLC</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fordan, Sally</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Supplemental</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HIV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Geenius</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Performance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Algorithm</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bennett, Berry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Meghan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crowe, Susanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Scheen, Marc ELSEVIER</subfield><subfield code="t">Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007727844</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:91</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:79-83</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcv.2017.04.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">91</subfield><subfield code="j">2017</subfield><subfield code="h">79-83</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Fordan, Sally |
| spellingShingle |
Fordan, Sally ddc 610 ddc 616.019405 bkl 44.45 Elsevier Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population |
| authorStr |
Fordan, Sally |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007727844 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 616 - Diseases |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 616.019405 OCLC 610 VZ 44.45 bkl Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm Elsevier |
| topic |
ddc 610 ddc 616.019405 bkl 44.45 Elsevier Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm |
| topic_unstemmed |
ddc 610 ddc 616.019405 bkl 44.45 Elsevier Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm |
| topic_browse |
ddc 610 ddc 616.019405 bkl 44.45 Elsevier Supplemental Elsevier HIV Elsevier Geenius Elsevier Performance Elsevier Algorithm |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b b bb m l ml s c sc |
| hierarchy_parent_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| hierarchy_parent_id |
ELV007727844 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007727844 |
| title |
Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population |
| ctrlnum |
(DE-627)ELV030212227 (ELSEVIER)S1386-6532(17)30115-4 |
| title_full |
Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population |
| author_sort |
Fordan, Sally |
| journal |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| journalStr |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
79 |
| author_browse |
Fordan, Sally |
| container_volume |
91 |
| physical |
5 |
| class |
610 610 DE-600 616.019405 OCLC 610 VZ 44.45 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Fordan, Sally |
| doi_str_mv |
10.1016/j.jcv.2017.04.005 |
| dewey-full |
610 616.019405 |
| title_sort |
comparative performance of the geenius™ hiv-1/hiv-2 supplemental test in florida's public health testing population |
| title_auth |
Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population |
| abstract |
• The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. |
| abstractGer |
• The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. |
| abstract_unstemmed |
• The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population |
| url |
https://doi.org/10.1016/j.jcv.2017.04.005 |
| remote_bool |
true |
| author2 |
Bennett, Berry Lee, Meghan Crowe, Susanne |
| author2Str |
Bennett, Berry Lee, Meghan Crowe, Susanne |
| ppnlink |
ELV007727844 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jcv.2017.04.005 |
| up_date |
2024-07-06T16:59:44.499Z |
| _version_ |
1803849757623320576 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030212227</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623204105.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2017.04.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017002000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030212227</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(17)30115-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.019405</subfield><subfield code="q">OCLC</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fordan, Sally</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The Geenius Supplemental assay is the first non-subjective rapid test in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay. • Based on this study, Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Supplemental</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HIV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Geenius</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Performance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Algorithm</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bennett, Berry</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Meghan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crowe, Susanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Scheen, Marc ELSEVIER</subfield><subfield code="t">Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007727844</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:91</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:79-83</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcv.2017.04.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">91</subfield><subfield code="j">2017</subfield><subfield code="h">79-83</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3995333 |